Study Summary
This trial is testing a new cancer treatment to see if it is safe and effective for people with advanced pancreatic cancer.
Eligible Conditions
- Pancreatic Cancer
- Pancreatic Adenocarcinoma
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: 1 year
1 year
Evaluate toxicity
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
Pancreatic Adenocarcinoma
1 of 1
Experimental Treatment
7 Total Participants · 1 Treatment Group
Primary Treatment: anti-EGFR-bispecific antibody armed activated T-cells · No Placebo Group · Phase 1
Pancreatic Adenocarcinoma
Drug
Experimental Group · 1 Intervention: anti-EGFR-bispecific antibody armed activated T-cells · Intervention Types: DrugTrial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year
Who is running the clinical trial?
University of VirginiaOTHER
689 Previous Clinical Trials
1,464,381 Total Patients Enrolled
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,834 Previous Clinical Trials
588,356 Total Patients Enrolled
Kenneth Yu, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:You have metastatic pancreatic cancer and have received at least first line chemotherapy
You have a platelet count of at least 75,000/mm^3.
Creatinine is less than 2.0 mg/dl
Total bilirubin is greater than 2 mg/dl.
Who else is applying?
What state do they live in?
| New York | 20.0% |
| Texas | 20.0% |
| California | 20.0% |
| Other | 40.0% |
How old are they?
| 18 - 65 | 100.0% |
What site did they apply to?
| University of Virginia (Specimen Analysis) | 100.0% |
What portion of applicants met pre-screening criteria?
| Met criteria | 100.0% |
References
- Park, Jeong A, Brian H Santich, Hong Xu, Lawrence G Lum, and Nai-Kong V Cheung. 2021. “Potent Ex Vivo Armed T Cells Using Recombinant Bispecific Antibodies for Adoptive Immunotherapy with Reduced Cytokine Release”. Journal for Immunotherapy of Cancer. BMJ. doi:10.1136/jitc-2020-002222.
- Park JA, Santich BH, Xu H, Lum LG, Cheung NV. Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release. J Immunother Cancer. 2021 May;9(5):e002222. doi: 10.1136/jitc-2020-002222.
- 2019. "A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04137536.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments